Swiss National Bank Increases Stake in Insmed, Inc. $INSM

Swiss National Bank boosted its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 8.1% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 625,912 shares of the biopharmaceutical company’s stock after buying an additional 46,800 shares during the quarter. Swiss National Bank’s holdings in Insmed were worth $102,349,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in INSM. Vanguard Group Inc. grew its stake in shares of Insmed by 5.7% in the fourth quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock worth $3,668,127,000 after acquiring an additional 1,140,524 shares in the last quarter. Darwin Global Management Ltd. increased its position in shares of Insmed by 2.3% during the fourth quarter. Darwin Global Management Ltd. now owns 20,933,277 shares of the biopharmaceutical company’s stock worth $3,644,274,000 after acquiring an additional 475,832 shares during the period. State Street Corp raised its stake in shares of Insmed by 30.6% in the fourth quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock valued at $905,312,000 after acquiring an additional 1,217,390 shares in the last quarter. RTW Investments LP raised its stake in shares of Insmed by 57.0% in the fourth quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock valued at $842,855,000 after acquiring an additional 1,758,321 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Insmed by 14.4% in the fourth quarter. Geode Capital Management LLC now owns 4,299,052 shares of the biopharmaceutical company’s stock valued at $751,936,000 after purchasing an additional 539,625 shares during the period.

Insider Buying and Selling at Insmed

In other Insmed news, CFO Sara Bonstein sold 2,404 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total transaction of $245,857.08. Following the transaction, the chief financial officer directly owned 69,082 shares of the company’s stock, valued at approximately $7,065,016.14. This trade represents a 3.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Michael Alexander Smith sold 1,806 shares of Insmed stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $95.82, for a total transaction of $173,050.92. Following the completion of the transaction, the insider owned 37,648 shares in the company, valued at approximately $3,607,431.36. This represents a 4.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 54,590 shares of company stock worth $5,793,738 in the last quarter. 2.10% of the stock is currently owned by company insiders.

Insmed Price Performance

Shares of NASDAQ INSM opened at $107.02 on Tuesday. The stock has a market cap of $23.20 billion, a P/E ratio of -18.61 and a beta of 0.78. Insmed, Inc. has a twelve month low of $90.39 and a twelve month high of $212.75. The stock has a 50 day moving average of $105.79 and a two-hundred day moving average of $135.16. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14. The business had revenue of $305.96 million for the quarter, compared to analyst estimates of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The company’s revenue for the quarter was up 229.7% compared to the same quarter last year. During the same period last year, the firm posted ($1.42) earnings per share. On average, research analysts forecast that Insmed, Inc. will post -2.43 earnings per share for the current year.

Wall Street Analyst Weigh In

INSM has been the subject of several analyst reports. Bank of America boosted their target price on Insmed from $211.00 to $213.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a research report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating and issued a $220.00 price objective on shares of Insmed in a research note on Monday. Guggenheim reissued a “buy” rating and set a $207.00 price objective on shares of Insmed in a research report on Friday, July 10th. Finally, Wells Fargo & Company boosted their price objective on Insmed from $160.00 to $161.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $209.13.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.